- New York US-NY
- [email protected]
Medical Research, Clinical Research, Executive Management
With a strong record in investigative medicine, Susan Kusek has orchestrated both clinical and nonclinical studies as well as new drug applications (NDAs) in the United States and other countries. Over the years, her work has spanned numerous practice areas, specializing in complex indications in cardiology, endocrinology, oncology, and transplant surgery. Since 2009, Susan Kusek has directed clinical operations for the NATPARA™ program at NPS Pharmaceuticals, Inc., headquartered in Bedminster, New Jersey. In her present role, Susan Kusek bears responsibility for conducting clinical trials investigating NATPARA™ recombinant parathyroid hormone (rhPTH 1-84) for treating subjects with hypoparathyroidism. Apart from managing a research program budget allocation, she manages many external vendors and four project managers who, in turn, supervise a variety of internal and external teams. On a daily basis, Ms. Kusek also oversees a critical Phase 3 study, ensuring that the program yields efficacy and safety results for filing an NDA. Susan Kusek brings nearly two decades of industry experience to her current position. From 2007 to 2009, she served as Director of Clinical Operations for Orion Clinical Services, Inc., in Princeton, New Jersey. During her tenure, she established a global strategy for all clinical operations and oversaw project managers responsible for clinical trial management. She also managed project teams that led more than 10 experimental research trials, five of which reached completion. Earlier in her professional life, Susan Kusek held posts at multinational powerhouses in the pharmaceutical industry, namely Bristol-Myers Squibb and a company within Johnson & Johnson Services, Inc. As a Registered Nurse (BSN), Ms. Kusek launched her career monitoring clinical oncology studies as a Clinical Research Associate with Princeton-based Theradex Systems, Inc. While there, she also acted as a Team Delegate for the National Cancer Institute and conducted quality-assurance audits.